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Objective: In patients with ischemic cardiomyopathy and a substantial amount of
dysfunctional but viable myocardium, myocardial revascularization may improve
left ventricular ejection fraction. The aim of this study was to evaluate why not all
patients with a substantial amount of viable tissue recover in function after revas-
cularization.
Methods: A total of 118 consecutive patients with a depressed left ventricular
ejection fraction (on average 29%  6%) due to chronic coronary artery disease
underwent myocardial revascularization. Before revascularization all patients un-
derwent dobutamine stress echocardiography to assess regional dysfunction,
left ventricular volumes, and myocardial viability as well as radionuclide
ventriculography to determine the left ventricular ejection fraction. Next, 3 to
6 months after revascularization, the left ventricular ejection fraction and
regional contractile function were reassessed. Improvement of left ventricular
ejection fraction  5% following revascularization was considered clinically
significant.
Results: Dobutamine stress echocardiography revealed that 489 (37%) of the 1329
dysfunctional segments were viable. A total of 61 (52%) patients had a sub-
stantial amount of viable myocardium (4 viable segments). In these 61 patients
the global function was expected to recover  5% after revascularization.
However, left ventricular ejection fraction did not improve in 20 (33%) of 61
patients despite the presence of substantial viability. Clinical characteristics and
echocardiographic data were comparable between patients with and without
improvement. However, patients without improvement had considerably larger
end systolic volumes (153  41 mL vs 133  46 mL, P  .007). The likelihood
of recovery of global function decreased proportionally with the increase of end
systolic volume (P  .001, R  0.43, n  61). Receiver operating characteristic
curve analysis demonstrated that an end systolic volume  140 mL had the
highest sensitivity/specificity to predict the absence of global recovery.
Conclusions: In patients with ischemic cardiomyopathy not only the amount of
dysfunctional but viable myocardium but also the extent of left ventricular remod-
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eling determines the improvement in function following myocardial revasculariza-
tion. Patients with a high end systolic volume due to left ventricular remodeling
have a decreased likelihood of improvement of global function.
Treatment of patients with heart failure andischemic left ventricular (LV) dysfunctionremains challenging; the prognosis of thesepatients is poor and proportionally decreaseswith the severity of LV dysfunction.1,2 Car-diac transplantation may substantially im-
prove clinical outcome; however, its clinical application is
limited by a shortage of donors.3 Myocardial revasculariza-
tion can be an alternative therapeutic option. Because of
advances in surgical techniques, and optimization of peri-
operative metabolic and mechanical support, coronary ar-
tery bypass grafting (CABG) is now more realistic in the
patients with the most severe LV dysfunction.4-7
It has become clear that approximately 50% of the pa-
tients with ischemic cardiomyopathy have a substantial
amount of hibernating myocardium.8,9 Myocardial contrac-
tility in this dysfunctional but viable tissue can be restored
by myocardial revascularization. In patients with a substan-
tial amount of dysfunctional but viable myocardium, CABG
may improve or even normalize LV ejection fraction
(LVEF).10,11 Moreover, revascularization may substantially
improve heart failure symptoms and prognosis.10,11 How-
ever, in daily clinical practice not all patients with ischemic
LV dysfunction recover in function after revascularization
despite the presence of substantial viable myocardium. Cur-
rently, the reasons for this absence of improvement after
CABG are not clear. Failure of recovery in patients with
considerable viable tissue may be related to an increased LV
volume due to extensive ventricular remodeling.12,13 To test
this hypothesis, patients with ischemic cardiomyopathy
were studied before and 3 to 6 months after myocardial
revascularization.
Methods
Patient Population, Study Protocol
The study population comprised 118 consecutive patients with a
depressed LVEF due to chronic coronary artery disease (confirmed
by angiography). All patients were already scheduled for myocar-
dial revascularization based on clinical grounds. Patients were in
clinically cardiac stable condition and were studied at least 6
months from previous myocardial infarction. Patients with primary
cardiomyopathy, significant valvular heart disease, or an inade-
quate acoustic window were not included in the study. Patients
who died perioperatively or during the follow-up were not in-
cluded in the study. A total of 5 patients died perioperatively (4
cardiac death, 1 sepsis); these patients had on average 9.8  2.2
dysfunctional segments and 3.8  3.0 dysfunctional but viable
segments. In these patients the LVEF was 23%  6%, the LV end
diastolic volume averaged 191  60 mL, and the LV end systolic
volume was 148  41 mL. The decision to perform surgical
revascularization was based on clinical grounds and coronary
angiography. Coronary artery bypass grafting was performed with
use of cardiopulmonary bypass in all patients. All patients were
operated on by standard techniques and optimization of perioper-
ative support. All patients underwent isolated CABG procedures
and patients having concomitant valve surgery were not included.
The study protocol was as follows. Before myocardial revas-
cularization all patients underwent rest and dobutamine stress
echocardiography to assess regional dysfunction, LV volumes, and
myocardial viability. Radionuclide ventriculography was used to
determine the exact LVEF before and 3 to 6 months after revas-
cularization. Before revascularization and at follow-up a structured
clinical interview was performed including assessment of the New
York Heart Association (NYHA) functional class. The Hospital
Ethics Committee approved the protocol and all patients gave
informed consent before the study.
Evaluation of Regional Function and Volumes
All echocardiograms were performed with a Sonos-5500 imaging
system (Andover, Mass) with a 1.8-MHz transducer using second
harmonic imaging to optimize endocardial border visualization.
Four standard views (apical 2- and 4-chamber views and paraster-
nal short- and long-axis views) were digitized on optical disks and
also stored on videotape. The end diastolic and end systolic LV
volumes were measured using the standard biplane Simpson method.
Assessment of Myocardial Viability
After baseline echocardiography, dobutamine was administered,
starting at a dose of 5 g/kg body weight per minute for 5 minutes,
followed by a 10 g/kg/min dose for 5 minutes (low-dose). Incre-
mental dobutamine doses of 10 g/kg/min were then given at
3-minute intervals up to a dose of 40 g/kg/min; atropine was
added if necessary. Test end points were: target heart rate, exten-
sive new wall motion abnormalities, ST-segment depression  2
mm, severe angina, systolic blood pressure fall40 mm Hg, blood
pressure 240/120 mm Hg, significant (supra)ventricular arrhyth-
mia. The echocardiograms were scored by 2 experienced reviewers
using a 16-segment model.14. Regional wall motion and systolic
wall thickening were scored on a 5-point scale: 1  normal, 2 
mild hypokinetic, 3  severe hypokinetic, 4  akinetic, 5 
dyskinetic. Myocardial segments were considered normal if the
regional wall motion was normal or mildly hypokinetic. Only
dysfunctional segments (severe hypokinesia, akinesia, or dyskine-
sia at resting echocardiography) were evaluated for myocardial
viability. Segments with an improvement, worsening, or a biphasic
wall motion response during stress echocardiography were con-
sidered viable. Segments with unchanged wall motion were con-
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sidered nonviable. A patient was classified as viable in the pres-
ence of 4 dysfunctional viable segments.8,10,15
Assessment of LVEF
LVEF was assessed by radionuclide ventriculography before and 3
to 6 months after revascularization. A small field-of-view gamma
camera system (Orbiter, Siemens, Erlangen, Germany) was used,
oriented in a 45° left anterior oblique position with a 5° to 10°
caudal tilt. After injection of technetium Tc 99m-pertechnate–
labeled autologous erythrocytes (550 MBq), radionuclide ventricu-
lography was performed at rest with the patient in supine position.
LVEF was calculated by standard methods (Odyssey VP, Picker,
Cleveland, Ohio). Improvement of LVEF 5% following revas-
cularization was considered clinically significant, as described
previously.10
Statistical Analysis
All continuous data were expressed as mean  SD and percent-
ages were rounded. Statistical analysis was performed with the
BMDP statistical software package (BMDP Statistical Software
Inc, Los Angeles, Calif). Continuous variables were compared
using the Student t test for unpaired samples. Differences between
proportions were compared using the chi-square test. Linear re-
gression analysis was used to determine the relation between end
systolic volume and change in LVEF. The LV volume that was
related to a low likelihood of improvement of LVEF postrevascu-
larization was determined by receiver operating characteristic
(ROC) curve analysis. The optimal cutoff value was the number of
segments that yielded the highest sum of sensitivity and specificity.
Multivariate analysis was performed to identify the relative con-
tributions of ventricular size and viability on the change in LVEF
after coronary bypass surgery. Dependent variable was change in
LVEF; independent variables were number of viable segments,
end systolic volume, and the end diastolic volume.
Results
Patient Characteristics
The clinical and echocardiographic characteristics of the
study population are presented in Table 1. The study group
consisted of 118 patients with ischemic cardiomyopathy (95
men, mean age 60  10 years). The majority of the patients
had a previous myocardial infarction, and all patients had
heart failure symptoms; the NYHA functional class was on
average 2.8  1.2. The range of preoperative ejection frac-
tion was 9% to 35%. A total of 73 (62%) patients had
angina. A total of 17 (14%) patients had previous coronary
artery bypass operations. A total of 3 patients had periop-
erative myocardial infarctions (by enzymatic criteria). Thir-
ty-eight patients needed inotropic support postoperatively.
An intra-aortic balloon pump was placed in 2 patients.
Ventricular assist devices were not used.
Contractile Function
Two-dimensional echocardiography was performed in 1888
segments, of which 559 (30%) had a normal contraction and
1329 (70%) segments had an abnormal contractile function.
Of the 1329 dysfunctional segments, 638 showed severe
hypokinesia, 690 akinesia, and 1 dyskinesia. Global func-
tion was severely depressed; the LVEF was on average 29%
 6%.
Myocardial Viability and Functional Outcome
Dobutamine stress echocardiography revealed that 489
(37%) of the dysfunctional segments were viable. Of the
489 dysfunctional but viable segments, 293 segments
showed a sustained improvement pattern during dobutamine
stimulation and the remaining 196 segments had an isch-
emic pattern. In the remaining 840 (63%) dysfunctional
segments, no myocardial viability was present. A total of 61
patients had a substantial amount of viable myocardium
(4 dysfunctional but viable segments). In these 61 patients
the global function was expected to recover (improvement
of LVEF  5%) after revascularization. However, although
41 (67%) of these patients had an improved LVEF follow-
ing revascularization, the LVEF did not improve in 20
patients despite the presence of a substantial amount of
viable myocardium. A total of 57 patients had 4 viable
segments and were considered nonviable.
TABLE 1. Baseline characteristics (n  118)
Clinical features
Age (y) 60 10
Male gender 95 (81%)
Previous infarction 109 (92%)
Number of stenosed arteries 2.7 0.6
NYHA functional class 2.8 1.2
Baseline LVEF 29% 6%
Number of viable segments 4.1 3.2
End diastolic volume (mL) 190 57
End systolic volume (mL) 133 46
LVEF, Left ventricular ejection fraction; NYHA, New York Heart Association.
Data are presented as mean  SD, or as numbers (%).
TABLE 2. Comparison of patients with a substantial
amount of viable myocardium with and without improve-
ment in function after revascularization
Clinical features
Patients with
improvement
(n  41)
Patients without
improvement
(n  20)
P
value
Age (y) 61 10 60 9 .84
Male gender 33 (80%) 16 (80%) 1
Previous infarction 35 (85%) 20 (100%) .18
Number of stenosed arteries 2.7 0.6 2.7 0.5 .54
NYHA functional class 2.8 1.2 3.1 1.2 .29
Baseline LVEF 28% 7% 28% 6% .78
Number of viable segments 6.7 2.5 6.7 2.0 .96
End diastolic volume (mL) 174 49 194 65 .18
End systolic volume (mL) 121 43 153 41 .007
LVEF, Left ventricular ejection fraction; NYHA, New York Heart Association.
Data are presented as mean  SD, or as numbers (%).
Schinkel et al Surgery for Acquired Cardiovascular Disease
The Journal of Thoracic and Cardiovascular Surgery ● Volume 127, Number 2 387
A
CD
Comparison of Viable Patients With and Without
Improvement
The patients with a substantial amount of viability were
divided into 2 groups: patients with and patients without
improvement in LVEF. Table 2 compares these 2 groups.
Clinical characteristics and echocardiographic data were
comparable between the 2 groups. However, improvement
of global function following revascularization was related to
the end systolic volume. Patients without improvement of
LVEF had considerably larger end systolic volumes com-
pared with the patients with recovery of global function
(153  41 ml vs 133  46 mL, P  .007). Patients with
improvement had after revascularization had on average 2.7
 0.6 stenosed coronary arteries, and patients without im-
provement had 2.7  0.5 stenosed vessels (P  .54).
Coronary artery target vessels were comparable in patients
with and without improvement following revascularization.
A total of 4 (7%) of the 61 patients with substantial viability
had a decrease  5% in LVEF. This was related to a
perioperative myocardial infarction in 3 patients and pro-
gression of LV dysfunction in 1 patient.
Of the total study population of 118 patients, 20 had LV
aneurysms or akinetic anterior walls that could have poten-
tially been treated with surgical ventricular remodeling in an
attempt to improve myocardial function. Of the 20 patients
with substantial viable myocardium but without improve-
ment in function following revascularization, 13 (65%) pa-
tients had a large anterior myocardial infarction that may
have derived benefit from ventricular remodeling proce-
dures. Overall, coronary bypass surgery markedly improved
symptoms; the angina scores (Canadian Cardiovascular
Score) improved from 2.9  0.8 before to 1.3  0.6 after
revascularization (P  .01). Heart failure symptoms also
improved: NYHA functional class changed from 2.8  1.2
before to 2.1  1.0 after surgery (P  .01). Of the total
study population of 118 patients (including the 57 patients
without viable myocardium), 63 patients did not improve in
LVEF and heart failure symptoms following revasculariza-
tion. However, angina symptoms improved significantly in
this patient subset; Canadian Cardiovascular Score de-
creased from 2.9  1.0 to 1.3  0.7 (P  .01).
Of the 57 patients with 4 viable segments, 7 (12%)
patients had an improved LVEF after revascularization.
These 7 patients all had 3 dysfunctional but viable segments
and a preserved end systolic volume (81  8 mL).
End Systolic Volume Versus Improvement of LVEF
Figure 1 demonstrates the relation between the end systolic
volume and the change in LVEF after revascularization in
the patients with a substantial amount of viable myocar-
dium. The likelihood of recovery of global function de-
creased proportionally with the increase of end systolic
volume (P  .001, R  0.43, n  61). ROC curve analysis
demonstrated that an end systolic volume  140 mL was
related to a low likelihood of improvement of LVEF pos-
trevascularization; the C-index was 0.75. This value of
140 mL had the highest sensitivity/specificity (68% and
65%, respectively) to predict the absence of global recov-
ery. Multivariate analysis showed the relative contributions
of ventricular size and viability on the LVEF after coronary
bypass surgery. Predictors of change in LVEF were number
of viable segments, hazard ratio 1.4, 95% confidence inter-
val [1.0-1.8] and end systolic volume (per mL), hazard ratio
0.038, 95% confidence interval [0.010-0.066]. The end
diastolic volume was not predictive. The best model to
predict LVEF was: LVEF change  2.15  1.4 · number of
viable segments  0.038 · end systolic volume.
Discussion
Medical therapy is still associated with a poor prognosis in
patients with ischemic cardiomyopathy.1,2 Cardiac trans-
plantation offers a good therapeutic option; however, many
patients who are eligible for transplantation will never re-
ceive a donor heart and die awaiting transplantation. Myo-
cardial revascularization can be a good alternative treatment
for patients with ischemic cardiomyopathy. Clearly, a care-
ful case selection by cardiac surgeons, anesthetists, and
cardiologists is mandatory. Several noninvasive techniques
have been developed to identify dysfunctional but viable
tissue (hibernating myocardium).16. Patients with a substan-
tial amount of dysfunctional but viable myocardium may
considerably improve in LVEF and prognosis following
Figure 1. Scatter plot indicating the relation between the end
systolic volume (in mL) and the LVEF change following myocar-
dial revascularization in the 61 patients with a substantial amount
of viability (R  0.43, P < .001).
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revascularization.10,11 However, in clinical practice not all
patients with a substantial amount of dysfunctional but
viable myocardium improve after revascularization. The
absence of recovery in patients with a considerable amount
of viable tissue may be related to an increased LV volume
due to extensive ventricular remodeling. To elucidate this
issue, a large group of patients with ischemic cardiomyop-
athy already scheduled for revascularization were evaluated
before and 3 to 6 months after revascularization. A total of
61 patients had a substantial amount of viable myocardium;
in these patients the global function was expected to recover
following revascularization. However, although the major-
ity of these patients had an improved LVEF following
revascularization, LVEF did not improve in 33% of these
patients. Comparison of the patients with and without im-
provement showed that clinical characteristics and echocar-
diographic data were comparable. Only the end systolic
volume was different between both groups; patients who did
not improve had significantly higher end systolic volumes.
An end systolic volume  140 mL had the highest sensi-
tivity/specificity to predict the absence of global recovery.
Multivariate analysis demonstrated that the number of via-
ble segments and end systolic volume were predictors of
change in LVEF after coronary bypass surgery. This may be
related to expansion of the infarcted area and adverse re-
modeling of the LV in patients with ischemic LV dysfunc-
tion.12,13
Previous Studies
The current results are in line with previous observations by
Louie and colleagues.12 In that study 22 patients with isch-
emic cardiomyopathy underwent myocardial revasculariza-
tion. In patients with a successful revascularization, the end
diastolic dimension was smaller than in patients with failed
revascularization (68  3 mm vs 81  4 mm, P  .05).
Yamaguchi and colleagues13 studied 20 patients with isch-
emic cardiomyopathy. Patients were divided into 2 groups
on the basis of the end systolic volume index. The mean
LVEF improved significantly after revascularization in pa-
tients with an end systolic volume index  100 mL/m2.
However, myocardial viability was not in this study.13 In the
present study, the preoperative end systolic volume dictated
the postoperative LV function, even in patients with a
substantial amount of dysfunctional but viable myocardium.
This may be caused by an increased wall stress and adverse
LV geometry. Restoration of myocardial blood flow may
not be capable of reversing myocardial function in these
segments. Nevertheless, Kim and colleagues17 have sug-
gested that patients with ischemic cardiomyopathy and LV
dilation should not be excluded from surgical revascular-
ization based on ventricular size alone. Due to revascular-
ization of viable myocardium, the remodeling process may
be stopped, resulting in an improved long-term survival,
even in the absence of improvement of function. In addition,
resection of nonviable scar tissue may also favorably influ-
ence survival. Randomized clinical trials, like the Surgical
Treatment for IsChemic Heart failure (STICH) trial, are
needed to assess the optimal treatment in these patients.18
Clinical Implications
Previous studies have demonstrated that a certain amount of
dysfunctional but viable tissue is needed for an improve-
ment of global function following revascularization.10,11,15
Usually a level of 4 viable segments is advised as a cutoff
value to predict improvement of LVEF.10,15 This cutoff
value represents approximately 25% of the LV and can be
used to identify patients who may benefit from revascular-
ization.10,15 The present study confirms the findings from
these previous studies. An enlarged end systolic volume
prevented global recovery, even in patients with substantial
viability. In these patients CABG could be combined with
resection of nonviable scar tissue. Traditionally, only dys-
kinetic regions (cardiac aneurysms) were excised and
closed. However, it was recognized that surgical reduction
of akinetic regions may reduce wall stress and improve the
geometry and LV function in selected patients.19,20 In pa-
tients with a previous anterior infarction, surgical anterior
ventricular endocardial restoration is a safe and effective
operation to restore geometry and reverse LV remodeling.20
Further studies are needed to determine the value of these
additional surgical procedures in patients with a substantial
amount of viable tissue.
The present data suggest that improvement may also
occur in patients with 4 viable segments. A total of 57
patients had 4 viable segments and were considered non-
viable. Interestingly, 7 of the nonviable patients had an
improved LVEF after revascularization. This was probably
related to the combination of 3 dysfunctional but viable
segments and a preserved end systolic volume in these
patients. Hence, the cutoff value of 4 viable segments is to
some extent arbitrary, because not only myocardial viability
but also remodeling and enlargement of the LV should be
considered. This may further improve case selection before
revascularization procedures in patients with ischemic car-
diomyopathy.
Techniques to Assess Viability
In the present study, dobutamine stress echocardiography
was used to assess myocardial viability. Although positron
emission tomography may be slightly more accurate for the
prediction of functional recovery after revascularization,
both techniques provide similar prognostic information and
accurately identify high-risk patients who may benefit from
revascularization.21 In particular, Allman and colleagues22
have demonstrated in a meta-analysis that no significant
difference in prognostic value between stress echocardiog-
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raphy and positron emission tomography existed. Recently,
magnetic resonance imaging combined with gadolinium-
based contrast agents was proposed to evaluate myocardial
viability.23 Importantly, LV volumes and the transmural
extent of viable/nonviable myocardium can be determined
with the high spatial resolution of magnetic resonance im-
aging. This may have important clinical implications as the
extent of transmural injury is related to functional improve-
ment after revascularization.
Study Limitations
Several limitations of this study have to be mentioned. First,
during bypass surgery an attempt was made to revascularize
all vessels with a significant stenosis; however, angiography
was not repeated at follow-up, and therefore graft occlusion
may have prevented functional recovery of viable segments.
Second, improvement in global function was assessed be-
fore and 3 to 6 months after revascularization. A longer
follow-up time may be needed for complete recovery of
contractile function in all dysfunctional but viable seg-
ments.24 Third, beta-blockers and angiotensin-converting
enzyme inhibition were used based on clinical grounds.
This may have influenced LV function; however, this re-
flects daily clinical practice. Finally, magnetic resonance
imaging may be more accurate than 2-dimensional echocar-
diography to assess LV volumes.
Conclusions
In patients with ischemic cardiomyopathy not only the
amount of dysfunctional but viable myocardium but also the
extent also LV remodeling and enlargement determines the
improvement in function following myocardial revascular-
ization. Patients with a high end systolic volume due to LV
remodeling have a decreased likelihood of improvement of
global function. Additional surgical procedures may be
needed to improve LV function in these patients.
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